Capricor Therapeutics inc (CAPR)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
The company published Revenue of $0.959903 millions, in thefourth quarter of 2022 financial report
CAPR delivered fourth quarter of 2022 operating deficit of $-8.066345 millions
Published Mar 18 2023
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
Capricor Therapeutics Inc has seen $0.959903 millions, in Revenue in the fiscal fourth quarter of 2022. For the fiscal fourth quarter of 2022 Capricor Therapeutics Inc realized net loss of $-7.721 million, higher than $-6.191 million a year ago.
Capricor Therapeutics Inc announced loss of $-29.02 millions and Revenues of $2.55 millions in the financial period 2022.
Net loss per share has widen to $-1.18 from $-0.87 in prior financial year, while Revenue doubled by 941.85 % from $0.24 millions a year ago.
Capricor Therapeutics Inc is expected to report next financial recent numbers on May 10, 2023.